Stockreport

Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF – At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events – – The data support furth [Read more]